Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-07-27 | Ms. Rossetti has served as a director of the Company since April 2022. She has served as a strategic consultant to Kala Pharmaceuticals, Inc. since October 2021, and from March 2018 to January 2019 was a consultant to Celgene Corporation. From June 2015 through July 2017, Ms. Rossetti held the position of Executive Vice President of Cell Machines, Inc., an early-stage biopharmaceutical company developing novel protein therapies where she assisted with the commercialization of technology for hemophilia and other diseases. Ms. Rossetti has held a number of positions within pharmaceutical commercial development, marketing, communications and finance, including Vice President of a Global Commercial Medicine Team at Pfizer Inc., from 2007 to 2012 where she led a global smoking cessation campaign. Ms. Rossetti previously served on the board of directors of Palatin Technologies, Inc., a public biopharmaceutical company, from June 2013 to December 2020. Ms. Rossetti currently holds positions as an adjunct Assistant Professor of Medical and Pharmaceutical Ethics at New York Medical College and an Adjunct Associate at Albert Einstein College of Medicine. Ms. Rossetti graduated from a joint program of the Albert Einstein College of Medicine and Benjamin N. Cardozo School of Law with an M.S. in Bioethics, has an M.B.A. from Columbia University Graduate School of Business and a B.A. in Biology and English from the University of Pennsylvania. We believe Ms. Rossetti is qualified to serve as our director because of her extensive experience in the pharmaceutical industry. |
| 2023-07-27 | Angela Rossetti, Director, age 70, Chair of the Nominating and Corporate Governance Committee. Director compensation for 2023 fiscal year: $138,000. |
| 2024-08-15 | Ms. Rossetti also received RSUs valued at $50,000 for her ongoing service as a Board member pursuant to our Director Compensation Policy. ... Ms. Rossetti earned $63,000 for her roles as a director, a member of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee and as the chair of our Nominating and Corporate Governance Committee. |
| Filing Date | Source Excerpt |
|---|---|
| 2013-05-15 | Angela Rossetti is a nominee for director. She is not currently a director and does not serve on any committees. No compensation is listed for Ms. Rossetti. |
| 2014-05-06 | Angela Rossetti has been a director since June 2013... Member of the nominating and corporate governance committee... Director compensation table shows total compensation of $16,411. |
| 2015-04-24 | Angela Rossetti has been a director since June 2013. ... Ms. Rossetti has extensive experience in worldwide development and marketing of specialty pharmaceuticals, including prefilled syringe products, and in communications and development of marketing and promotional plans. |
| 2016-04-22 | Angela Rossetti has been a director of Palatin since June 2013. ... (1) Member of the audit committee. (3) Member of the nominating and corporate governance committee. ... Angela Rossetti received $43,000 in fees earned or paid in cash, $21,600 in stock awards, and $13,984 in option awards, totaling $78,584. |
| 2017-04-28 | Angela Rossetti has been a director of Palatin since June 2013. In June 2015 she became Executive Vice President of Cell Machines, Inc., an early stage biopharmaceutical company developing transformational biosimilars and novel protein therapies. Previously, Ms. Rossetti served in pharmaceutical marketing, communications and financial roles, including as Vice President at Pfizer Inc., where she led a global commercial medicine team for smoking cessation, and as an Assistant Vice President at Wyeth, managing a global hemophilia business. Previously, she was President of Ogilvy Healthworld, an advertising business in the pharmaceutical and biotechnology sectors, and served on the Biotech and Pharmaceutical Advisory Board of Danske Capital for six years. In May 2016 Ms. Rossetti was appointed as a member of the board of directors of Viramal Limited, a privately held London-based emerging pharmaceutical company, and is currently acting chair of the board of directors. Ms. Rossetti graduated from a joint program of the Albert Einstein College of Medicine and Benjamin N. Cardozo School of Law with an M.S.in Bioethics in 2014, has an M.B.A. in Finance from Columbia University Graduate School of Business and a B.A. in Biology from the University of Pennsylvania, and is an adjunct Assistant Professor at New York Medical College. |
| 2018-05-17 | ANGELA ROSSETTI has been a director of Palatin since June 2013... Audit committee includes Ms. Rossetti... Nominating and corporate governance committee includes Ms. Rossetti... Compensation table shows total compensation of $82,726. |
| 2019-05-10 | Angela Rossetti has been a director of Palatin since June 2013. Ms. Rossetti consults with pharmaceutical companies, including consultation on rare disease indications and utilization in low- and middle-income markets. From June 2015 through July 2017, she served as Executive Vice President of Cell Machines, Inc., an early stage biopharmaceutical company developing novel protein therapies. Previously, Ms. Rossetti served in pharmaceutical marketing, communications and financial roles, including as Vice President at Pfizer Inc., where she led a global commercial medicine team for smoking cessation, and as an Assistant Vice President at Wyeth, managing a global hemophilia business. Previously, she was President of Ogilvy Healthworld, an advertising business in the pharmaceutical and biotechnology sectors, and served on the Biotech and Pharmaceutical Advisory Board of Danske Capital for six years. Ms. Rossetti graduated from a joint program of the Albert Einstein College of Medicine and Benjamin N. Cardozo School of Law with an M.S.in Bioethics in 2014, has an M.B.A. in Finance from Columbia University Graduate School of Business and a B.A. in Biology from the University of Pennsylvania, and is an adjunct Assistant Professor at New York Medical College. Ms. Rossetti serves on the Audit Committee and the Nominating and Corporate Governance Committee. For fiscal 2018, Ms. Rossetti received total compensation of $140,275. |
| 2020-05-11 | Angela Rossetti has been a director of Palatin since June 2013. She is a member of the audit committee and the nominating and corporate governance committee. For fiscal 2019, she received total compensation of $138,300. |
Data sourced from SEC filings. Last updated: 2026-02-03